Compare SWBI & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWBI | ETON |
|---|---|---|
| Founded | 1852 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 691.4M | 689.8M |
| IPO Year | 2000 | 2018 |
| Metric | SWBI | ETON |
|---|---|---|
| Price | $14.56 | $29.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $14.00 | ★ $39.33 |
| AVG Volume (30 Days) | ★ 405.2K | 370.8K |
| Earning Date | 06-17-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $474,661,000.00 | $79,950,000.00 |
| Revenue This Year | $7.61 | $40.90 |
| Revenue Next Year | $3.72 | $47.23 |
| P/E Ratio | $291.20 | ★ N/A |
| Revenue Growth | N/A | ★ 104.94 |
| 52 Week Low | $7.73 | $13.09 |
| 52 Week High | $15.79 | $32.31 |
| Indicator | SWBI | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 44.96 | 64.45 |
| Support Level | $13.80 | $15.79 |
| Resistance Level | $15.24 | N/A |
| Average True Range (ATR) | 0.41 | 1.53 |
| MACD | -0.12 | 0.47 |
| Stochastic Oscillator | 18.00 | 70.34 |
Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.